Neurofibromin

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 17: Line 17:
The two conformations that neurofibromin exists in are the open state and closed state. The conformational change of neurofibromin involves rearrangement of the domains.
The two conformations that neurofibromin exists in are the open state and closed state. The conformational change of neurofibromin involves rearrangement of the domains.
=====Closed Conformation=====
=====Closed Conformation=====
-
The <scene name='90/904326/Overview_of_domains/1'>closed state</scene> of neurofibromin has both protomers in a closed conformation, which inhibits the binding of Ras to the GRD of neurofibromin due to the HEAT/ARM core blocking the GRD. A metal binding site between the N-HEAT/ARM domain and the GRD-Sec14-PH linker stabilize the closed conformation. This site is coordinated by three residues, <scene name='90/904325/Triad/1'>C1032, H1558, and H1576,</scene>, and a water molecule. (Figure 2). This binding site is preferential for zinc- zinc has been found to stabilize the closed conformation of neurofibromin. In the absence of zinc, neurofibromin is in the open conformation. <ref name="Naschberger"/>
+
The <scene name='90/904326/Overview_of_domains/1'>closed state</scene> of neurofibromin has both protomers in a closed conformation, which inhibits the binding of Ras to the GRD of neurofibromin due to the HEAT/ARM core blocking the GRD. A metal binding site between the N-HEAT/ARM domain and the GRD-Sec14-PH linker stabilize the closed conformation. This site is coordinated by three residues, <scene name='90/904325/Triad/1'>C1032, H1558, and H1576,</scene>. (Figure 2). This binding site is preferential for zinc- zinc has been found to stabilize the closed conformation of neurofibromin. In the absence of zinc, neurofibromin is in the open conformation. <ref name="Naschberger"/>
[[Image:greenTriad.png|200 px|thumb|Figure 2. Triad of Residues that keep Neurofibromin in the Closed Conformation.]]
[[Image:greenTriad.png|200 px|thumb|Figure 2. Triad of Residues that keep Neurofibromin in the Closed Conformation.]]
=====Open Conformation=====
=====Open Conformation=====

Revision as of 12:38, 21 April 2022

Neurofibromin (7pgs) Homo dimeric structure colored to differentiate dimers

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 Bergoug M, Doudeau M, Godin F, Mosrin C, Vallee B, Benedetti H. Neurofibromin Structure, Functions and Regulation. Cells. 2020 Oct 27;9(11). pii: cells9112365. doi: 10.3390/cells9112365. PMID:33121128 doi:http://dx.doi.org/10.3390/cells9112365
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Naschberger A, Baradaran R, Rupp B, Carroni M. The structure of neurofibromin isoform 2 reveals different functional states. Nature. 2021 Nov;599(7884):315-319. doi: 10.1038/s41586-021-04024-x. Epub 2021, Oct 27. PMID:34707296 doi:http://dx.doi.org/10.1038/s41586-021-04024-x
  3. Trovo-Marqui AB, Tajara EH. Neurofibromin: a general outlook. Clin Genet. 2006 Jul;70(1):1-13. doi: 10.1111/j.1399-0004.2006.00639.x. PMID:16813595 doi:http://dx.doi.org/10.1111/j.1399-0004.2006.00639.x
  4. Hall BE, Bar-Sagi D, Nassar N. The structural basis for the transition from Ras-GTP to Ras-GDP. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12138-42. Epub 2002 Sep 4. PMID:12213964 doi:http://dx.doi.org/10.1073/pnas.192453199
  5. Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2018;148:799-811. doi: 10.1016/B978-0-444-64076-5.00051-X. PMID:29478615 doi:http://dx.doi.org/10.1016/B978-0-444-64076-5.00051-X
  6. Yoshimura SH, Hirano T. HEAT repeats - versatile arrays of amphiphilic helices working in crowded environments? J Cell Sci. 2016 Nov 1;129(21):3963-3970. doi: 10.1242/jcs.185710. Epub 2016 Oct , 6. PMID:27802131 doi:http://dx.doi.org/10.1242/jcs.185710
  7. 7.0 7.1 7.2 Lupton CJ, Bayly-Jones C, D'Andrea L, Huang C, Schittenhelm RB, Venugopal H, Whisstock JC, Halls ML, Ellisdon AM. The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1. Nat Struct Mol Biol. 2021 Dec;28(12):982-988. doi: 10.1038/s41594-021-00687-2., Epub 2021 Dec 9. PMID:34887559 doi:http://dx.doi.org/10.1038/s41594-021-00687-2
  8. Scheffzek K, Welti S. Pleckstrin homology (PH) like domains - versatile modules in protein-protein interaction platforms. FEBS Lett. 2012 Aug 14;586(17):2662-73. doi: 10.1016/j.febslet.2012.06.006. Epub , 2012 Jun 19. PMID:22728242 doi:http://dx.doi.org/10.1016/j.febslet.2012.06.006
  9. Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7497-502. doi:, 10.1073/pnas.1607298113. Epub 2016 Jun 16. PMID:27313208 doi:http://dx.doi.org/10.1073/pnas.1607298113
  10. Frech M, Darden TA, Pedersen LG, Foley CK, Charifson PS, Anderson MW, Wittinghofer A. Role of glutamine-61 in the hydrolysis of GTP by p21H-ras: an experimental and theoretical study. Biochemistry. 1994 Mar 22;33(11):3237-44. doi: 10.1021/bi00177a014. PMID:8136358 doi:http://dx.doi.org/10.1021/bi00177a014
  11. Bunda S, Burrell K, Heir P, Zeng L, Alamsahebpour A, Kano Y, Raught B, Zhang ZY, Zadeh G, Ohh M. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat Commun. 2015 Nov 30;6:8859. doi: 10.1038/ncomms9859. PMID:26617336 doi:http://dx.doi.org/10.1038/ncomms9859
  12. Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev Period Med. 2014 Jul-Sep;18(3):297-306. PMID:25182393
  13. Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2018;148:799-811. doi: 10.1016/B978-0-444-64076-5.00051-X. PMID:29478615 doi:http://dx.doi.org/10.1016/B978-0-444-64076-5.00051-X
  14. Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Med Clin North Am. 2019 Nov;103(6):1035-1054. doi: 10.1016/j.mcna.2019.07.004. PMID:31582003 doi:http://dx.doi.org/10.1016/j.mcna.2019.07.004
  15. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. doi:, 10.1016/j.bbamcr.2006.10.001. Epub 2006 Oct 7. PMID:17126425 doi:http://dx.doi.org/10.1016/j.bbamcr.2006.10.001

Proteopedia Page Contributors and Editors (what is this?)

Jordyn K. Lenard, Ryan D. Adkins, Michal Harel, OCA, Jaime Prilusky

Personal tools